Survival is generally prolonged after targeted therapy for breast cancer liver metastasis, and the length of survival varies from person to person. As the most prevalent malignant tumor in women worldwide, breast cancer is a serious health hazard for women. Among newly diagnosed breast cancer patients, 6% to 7% are accompanied by metastasis to distant organs. Among the distant metastatic sites, the incidence of liver metastasis is only lower than that of bone metastasis and lung metastasis. Breast cancer with liver metastasis is advanced, and some studies say that if distant metastasis occurs, the median survival time of breast cancer patients is 18 to 24 months. The treatment of advanced breast cancer requires multidisciplinary comprehensive treatment, and it is recommended to make a decision after comprehensive evaluation of the disease (such as biological indicators of breast cancer, CT, MRI, etc.). There are fewer studies on the prognosis of patients with breast cancer combined with liver metastasis after targeted therapy. According to a study in China, the median overall survival of patients with advanced breast cancer treated with amlotinib regimen is 5.4 months; another study says that the median progression-free survival of patients with breast cancer combined with liver metastasis is 25 months after active treatment. It is recommended to go to a regular hospital to evaluate the condition and follow the doctor’s instructions to actively cooperate with the treatment, so as to avoid delaying the condition. Please strictly follow the doctor’s instructions for medication, and do not use medication on your own.